As TIM3 is more likely to directly affect the interaction of CTL with their tumor cell targets as discussed in the introduction, we selected TIM3 blockade as an adjunct treatment to improve responses to A2AR-antagonism. The gene discussed is HAVCR2; the disease is neoplasm.